In complicated UTIs, cefepime-taniborbactam increased treatment success vs. meropenem at 19 to 23 d.

Granwehr, Bruno

Granwehr, Bruno.

Affiliation

Granwehr B; University of Texas MD Anderson Cancer Center, Houston, Texas, USA (B.G.).

Ann Intern Med ; 177(6): JC67, 2024 Jun.

Article in En | MEDLINE | ID: mdl-38830218

ABSTRACT

ABSTRACT

SOURCE CITATION Wagenlehner FM, Gasink LB, McGovern PC, et al; CERTAIN-1 Study Team. Cefepime-taniborbactam in complicated urinary tract infection. N Engl J Med. 2024;390611-622. 38354140.

Subject(s)

Anti-Bacterial Agents; Cefepime; Meropenem; Urinary Tract Infections; Female; Humans; Male; Middle Aged; Anti-Bacterial Agents/therapeutic use; Anti-Bacterial Agents/adverse effects; Cefepime/therapeutic use; Drug Combinations; Meropenem/therapeutic use; Treatment Outcome; Urinary Tract Infections/drug therapy; Randomized Controlled Trials as Topic

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Tract Infections / Cefepime / Meropenem / Anti-Bacterial Agents Limits: Female / Humans / Male / Middle aged Language: En Journal: Ann Intern Med Year: 2024 Document type: Article

Fulltext

XML

PubMed Links

Search on Google